Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 4Completed 2Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 6Myeloid 4Sarcoma 2Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

venetoclax 33fludarabine 32Cyclophosphamide 31Azacitidine 29Specimen Handling 27Biopsy 19Cytarabine 18fludarabine phosphate 15Whole-Body Irradiation 15Stem Cell Transplantation 15Decitabine 15ruxolitinib 14Tacrolimus 14Melphalan 14Busulfan 14Mycophenolic Acid 13asciminib 10Injections 10decitabine and cedazuridine drug combination 8Thiotepa 8Methotrexate 8Hematopoietic Stem Cell Transplantation 8X-Rays 7Granulocyte Colony-Stimulating Factor 7Magnetic Resonance Spectroscopy 6Idarubicin 6Filgrastim 6Cyclosporine 6Blood Specimen Collection 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × olverembatinib × Myeloid × Clear all
NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Peking University People's Hospital

Recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05521204 2022-08-30

Olverembatinib for FGFR1-rearranged Neoplasms

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
20 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡